Pharmaceutical firms reveal IP challenges in personalised medicine
European in-house counsel at Novartis, DSM and other generics and originator manufacturers tell Managing IP about the prospects and problems of individual treatments, particularly as AI plays a bigger role in making them
Personalised therapies are gaining great attention in the medical sphere but are raising big intellectual property challenges for drug manufacturers, according to in-house counsel.
Technology has reached a point where pharmaceutical companies can more accurately map out the genetics of...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.